Pipeline
Product Development Portfolio
Inflammation
-
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
ABX464 Phase 2b completed; Phase 3 to start in Q4 2021Description/Summary:
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in Phase 2a and Phase 2b induction trials to treat ulcerative colitis (UC). Patients who completed the induction studies had the option to roll over into the respective open-label extension studies.
Milestones:
- Phase 2a data from 12- and 24-months maintenance study reported
- Phase 2b data from induction study reported
-
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
ABX464 Phase 2a completed; Phase 2b in preparationDescription/Summary:
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in the completed Phase 2a and Phase 2b induction studies as well as in long-term maintenance studies in patients with moderate-to-severe ulcerative colitis (UC). In addition to the clinical observations in UC patients, Abivax generated excellent phase 2a clinical results in RA, following the promising pre-clinical data from collagen-induced arthritis animal models.
Milestones:
- Phase 2a study results reported
-
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
ABX464 Phase 2b pivotal study in preparationDescription/Summary:
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in the completed Phase 2a and Phase 2b induction studies as well as in ongoing long-term maintenance studies in patients with moderate-to-severe ulcerative colitis (UC).
Due to the clinical similarities of Crohn’s disease (CD) and UC, and the predictability of the DSS model for both UC and CD, several key opinion leaders (KOLs) are confident that ABX464 will also show beneficial effects in patients suffering from CD.
Antiviral
-
Respiratory Syncytial Virus Antiviral drug
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
-
Dengue Antiviral drug
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
-
Influenza Antiviral drug
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
Cancer
-
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
ABX196 in Phase 1/2 POC clinical trial in HCC ongoingDescription/Summary:
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer models.
Milestones:
- Phase 1/2 trial ongoing